 |
||
  |
|
|
 |
 |
 |
 |
 |
 |
 |
|
 |
 |
 |
|
 |
|
|
|
 | |
Other publications of interest
Luellen BA, Miller DB, Chisnell AC, Murphy DL, O'Callaghan JP, Andrews AM. Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine . J pharmacol Exp Ther, 307:923-931, 2003.
Lee SY, Andoh T, Murphy DL, Chiueh CC.17beta-estradiol activates ICI 182, 780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection. FASEB J, 17:947-948, 2003.
Schmidt PJ, Raju J, Danaceau M, Murphy DL, Berlin RE. The effects of gender and gonadal steroids on the neuroendocrine and temperature response to m-chlorophenylpiperazine in leuprolide-induced hypogonadism in women and men. Neuropsychopharmacology, 27:800-812, 2002.
Unger EL, Mazzola-Pomietto P, Murphy DL, Andrews AM. 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats:
a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine]. J Pharmacol Exp Ther, 303:527-533, 2002.
Lesch, K.-P., Gross, J., Wolozin, B.L., Franzek, E., Bengel, D., Riederer, P., and Murphy, D.L.: Direct sequencing of the reserpine-sensitive vesicular monoamine transporter complementary DNA in unipolar depression and manic-depressive illness. Psychiatr. Gen. 4: 153-160, 1994.
Lesch, K.-P., Balling, U., Gross, J., Strauss, K., Wolozin, B.L., Murphy, D.L., and Riederer, P.: Organization of the human serotonin transporter gene. J. Neural Transm. 95: 157-162, 1994.
Lesch, K.-P., Wolozin, B.L., Murphy, D.L., and Riederer, P.: Primary structure of the human platelet serotonin uptake site: Identity with the brain serotonin transporter. J. Neurochem. 60: 2319-2322, 1993.
Collins, F.A., Murphy, D.L., Reiss, A.L., Sims, K.B., Lewis, J.G., Freund, L., Karoum, F., Zhu, D., Maumenee, I.H., and Antonarakis, S.E.: Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. Am. J. Med. Genet. 42: 127-134, 1992.
Murphy, D.L., Sims, K.B., Karoum, F., de la Chapelle, A., Norio, R., Sankila, E.-M., and Breakefield, X.O.: Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J. Neurochem. 54: 242-247, 1990.
Sims, K.B., Ozelius, L., Corey, T., Rinehart, W.B., Liberfarb, R., Haines, J., Chen, W.J., Norio, R., Sankila, E., de la Chapelle, A., Murphy, D.L., Gusella, J., and Breakefield, X.O.: Norrie disease gene is distinct from the monoamine oxidase genes. Am. J. Hum. Genet. 45: 424-434, 1989.
Sims, K.B., de la Chapelle, A., Norio, R., Sankila, E.-M., Hsu, Y.-P.P., Rinehart, W.B., Corey, T.J., Ozelius, L., Powell, J.F., Bruns, G., Gusella, J.F., Murphy, D.L., and Breakefield, X.O.: Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron 2: 1069-1076, 1989.
| ||||||
|
